{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:01:07Z","timestamp":1792270867498,"version":"4.4.0"},"reference-count":43,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25am0521010"],"award-info":[{"award-number":["JP25am0521010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25ama121008"],"award-info":[{"award-number":["JP25ama121008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25ama221153"],"award-info":[{"award-number":["JP25ama221153"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25ama221339"],"award-info":[{"award-number":["JP25ama221339"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25bm1123027"],"award-info":[{"award-number":["JP25bm1123027"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research","award":["25K10553"],"award-info":[{"award-number":["25K10553"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>CD44 variant (CD44v) isoforms are involved in promoting cancer metastasis, sustaining cancer stem cell (CSC) properties, and conferring resistance to therapeutic interventions. Consequently, the development of monoclonal antibodies (mAbs) targeting CD44v represents a crucial strategy for eliminating CD44v-positive cancer cells. Previously, an anti-CD44v6 mAb, C44Mab-9 (mouse IgG1, \u03ba), was established. C44Mab-9 recognizes explicitly the epitope encoded by the variant exon 6-encoded region of CD44 and applies to flow cytometry, western blotting, and immunohistochemistry. To assess the therapeutic potential, a mouse IgG2a isotype of C44Mab-9 (designated C44Mab-9-mG2a) was generated, and the in vitro and in vivo antitumor activities were evaluated using gastric and colorectal cancer cell lines. C44Mab-9-mG2a demonstrated specific binding to CD44v3\u201310-overexpressed Chinese hamster ovary cells (CHO\/CD44v3\u201310), as well as gastric cancer (NUGC-4) and colorectal cancer (COLO201 and COLO205) in flow cytometry. C44Mab-9-mG2a exerted antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against CHO\/CD44v3\u201310, NUGC-4, COLO201, and COLO205. Moreover, systemic administration of C44Mab-9-mG2a significantly inhibited tumor growth in CHO\/CD44v3\u201310, NUGC-4, COLO201, and COLO205 xenografts compared with the control IgG2a. These findings indicate that C44Mab-9-mG2a could be applied to the mAb-based therapy against CD44v6-positive tumors.<\/jats:p>","DOI":"10.3390\/cells14231873","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T15:56:41Z","timestamp":1764172601000},"page":"1873","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic Potential of an Anti-CD44v6 Monoclonal Antibody in Xenograft Models of Colorectal and Gastric Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Aoi","family":"Hirayama","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-4474","authenticated-orcid":false,"given":"Tomokazu","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Laboratory of Oncology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Shinoda","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kojo","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruto","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/0092-8674(89)90638-7","article-title":"A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family","volume":"56","author":"Stamenkovic","year":"1989","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1004","article-title":"CD44: From adhesion molecules to signalling regulators","volume":"4","author":"Ponta","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7970","DOI":"10.1111\/febs.16179","article-title":"The state of CD44 activation in cancer progression and therapeutic targeting","volume":"289","author":"Guo","year":"2021","journal-title":"FEBS J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.matbio.2006.08.261","article-title":"Hyaluronan-mediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways","volume":"26","author":"Slevin","year":"2007","journal-title":"Matrix Biol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hassn Mesrati, M., Syafruddin, S.E., Mohtar, M.A., and Syahir, A. (2021). CD44: A Multifunctional Mediator of Cancer Progression. Biomolecules, 11.","DOI":"10.3390\/biom11121850"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.biocel.2016.09.009","article-title":"CD44: More than a mere stem cell marker","volume":"81","author":"Morath","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1083\/jcb.128.4.687","article-title":"CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor","volume":"128","author":"Bennett","year":"1995","journal-title":"J. Cell Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1101\/gad.242602","article-title":"CD44 is required for two consecutive steps in HGF\/c-Met signaling","volume":"16","author":"Chen","year":"2002","journal-title":"Genes. Dev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2011.01.038","article-title":"CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth","volume":"19","author":"Ishimoto","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","article-title":"Metastasis-Initiating Cells and Ecosystems","volume":"11","author":"Ganesh","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41591-020-01195-4","article-title":"Targeting metastatic cancer","volume":"27","author":"Ganesh","year":"2021","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41419-018-1265-7","article-title":"CD44v6 engages in colorectal cancer progression","volume":"10","author":"Ma","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stem.2014.01.009","article-title":"CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis","volume":"14","author":"Todaro","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s002620050329","article-title":"Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas","volume":"43","author":"Heider","year":"1996","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/0959-8049(95)00420-3","article-title":"Splice variants of the cell surface glycoprotein CD44 associated with metastatic tumour cells are expressed in normal tissues of humans and cynomolgus monkeys","volume":"31","author":"Heider","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wang, Z., Tang, Y., Xie, L., Huang, A., Xue, C., Gu, Z., Wang, K., and Zong, S. (2019). The Prognostic and Clinical Value of CD44 in Colorectal Cancer: A Meta-Analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00309"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.10369","article-title":"Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts","volume":"99","author":"Verel","year":"2002","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.oraloncology.2007.10.009","article-title":"Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma","volume":"44","author":"Riechelmann","year":"2008","journal-title":"Oral. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1158\/1078-0432.CCR-06-0910","article-title":"A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus","volume":"12","author":"Tijink","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1043","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eabg3072","DOI":"10.1126\/scitranslmed.abg3072","article-title":"Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies","volume":"14","author":"Greco","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Porcellini, S., Asperti, C., Corna, S., Cicoria, E., Valtolina, V., Stornaiuolo, A., Valentinis, B., Bordignon, C., and Traversari, C. (2020). CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00099"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Saeidpour Masouleh, S., Nasiri, K., Ostovar Ravari, A., Saligheh Rad, M., Kiani, K., Sharifi Sultani, A., Nejati, S.T., and Nabi Afjadi, M. (2025). Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma. Biomark. Res., 13.","DOI":"10.1186\/s40364-025-00783-1"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Ciulean, I.S., Fischer, J., Quaiser, A., Bach, C., Abken, H., Tretbar, U.S., Fricke, S., Koehl, U., Schmiedel, D., and Grunwald, T. (2023). CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1290488"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ejima, R., Suzuki, H., Tanaka, T., Asano, T., Kaneko, M.K., and Kato, Y. (2023). Development of a Novel Anti-CD44 Variant 6 Monoclonal Antibody C(44)Mab-9 for Multiple Applications against Colorectal Carcinomas. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24044007"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijmm.2023.5221","article-title":"Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models","volume":"51","author":"Li","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kaneko, M.K., Suzuki, H., Ohishi, T., Nakamura, T., Tanaka, T., and Kato, Y. (2024). A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25031941"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","article-title":"CD44, a therapeutic target for metastasising tumours","volume":"46","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1158\/1078-0432.CCR-24-1977","article-title":"Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET\/CD44v6","volume":"31","author":"Maurya","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10238-025-01611-4","article-title":"CD44v6-mediated regulation of gastric cancer stem cells: A potential therapeutic target","volume":"25","author":"Chen","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1089\/hum.2020.216","article-title":"Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer","volume":"32","author":"Stornaiuolo","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_33","first-page":"169","article-title":"CD44 glycoproteins in colorectal cancer: Expression, function, and prognostic value","volume":"77","author":"Wielenga","year":"2000","journal-title":"Adv. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pan, T., Zhu, J., Wang, X., Tang, D., Wang, Z., Yang, Y., Teng, Y., Tian, Q., Dan, G., and Chen, C. (2025). MEN1 Promotes Ferroptosis by Disrupting CD44 Alternative Splicing to Suppress Lung Cancer. Cancer Res., in press.","DOI":"10.1158\/0008-5472.CAN-25-0021"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1158\/0008-5472.CAN-05-0207","article-title":"A five-amino-acid peptide blocks Met- and Ron-dependent cell migration","volume":"65","author":"Matzke","year":"2005","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1182\/blood-2009-04-219204","article-title":"A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis","volume":"114","author":"Tremmel","year":"2009","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00204-014-1424-2","article-title":"Perspectives of CD44 targeting therapies","volume":"89","author":"Ponta","year":"2015","journal-title":"Arch. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32532","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"80046","DOI":"10.18632\/oncotarget.11098","article-title":"First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors","volume":"7","author":"Coveler","year":"2016","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-14-2141","article-title":"CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients","volume":"21","author":"Birzele","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1073\/pnas.1221841110","article-title":"Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44","volume":"110","author":"Zhang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/mab.2023.0033","article-title":"Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H2Mab-250\/H2CasMab-2 for Breast Cancers","volume":"43","author":"Kaneko","year":"2024","journal-title":"Monoclon. Antibodies Immunodiagn. Immunother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.stem.2025.05.007","article-title":"Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy","volume":"32","author":"Hosking","year":"2025","journal-title":"Cell Stem Cell"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/23\/1873\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T05:30:05Z","timestamp":1764307805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/23\/1873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":43,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cells14231873"],"URL":"https:\/\/doi.org\/10.3390\/cells14231873","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}